DFO
ITCI

Duquesne Family Office’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Duquesne Family Office’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-296,986
Closed -$6.45M – 46
2018
Q3 		$6.45M Hold
296,986
– – 0.31% 30
2018
Q2 		$5.25M Hold
296,986
– – 0.25% 32
2018
Q1 		$6.25M Buy
+296,986
New +$5.79M 0.35% 21

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Duquesne Family Office's ITCI Position: Q4 2018 in Review

Duquesne Family Office sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2018, closing a stake of 296,986 shares — an estimated $6.45M sold.

Duquesne Family Office first reported a position in ITCI in Q1 2018 and held it in 3 quarters. The position peaked at $6.45M in Q3 2018. 127 funds tracked by Wall St. Rank hold ITCI as of Q4 2018.

  • Duquesne Family Office reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2018 after selling out during the quarter.
  • Duquesne Family Office sold 296,986 Intra-Cellular Therapies Inc. shares in Q4 2018, an estimated $6.45M.
  • Duquesne Family Office first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 3 quarters.
  • Duquesne Family Office's Intra-Cellular Therapies Inc. position peaked at $6.45M in Q3 2018.
  • 127 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2018.

Based on Duquesne Family Office's 13F filing for Q4 2018, filed 14 Feb 2019.